Repurposing Valrubicin as a Potent Inhibitor of Ovarian Cancer Cell Growth

• Published in: Anticancer research Vol. 44; no. 10; p. 4301
• Main Authors: Lee, Jaeeun, Heo, Kyun
• Format: Journal Article
• Language: English
• Published: Greece 01-10-2024
• Subjects: Antineoplastic Agents - pharmacology; Apoptosis - drug effects; Cell Line, Tumor; Cell Proliferation - drug effects; Drug Repositioning; Female; Humans; Ovarian Neoplasms - drug therapy; Ovarian Neoplasms - pathology; Valrubicin; apoptosis; drug repositioning; ovarian cancer
• ISSN: 1791-7530
• DOI: 10.21873/anticanres.17259

Ovarian cancer (OC) is a leading cause of cancer-related mortality among women, and there remains a significant unmet need for new therapeutic agents to improve patient outcomes. This study aimed to explore drug repositioning by screening a library of Food and Drug Administration (FDA)-approved compounds to identify those with therapeutic potential against OC. We also aimed to elucidate the molecular mechanisms of action of such compounds to better understand how they inhibit cancer cell proliferation.
Using the WST-1 assay, a library of 1710 FDA-approved drugs was screened to evaluate their effects on OC cell proliferation. The molecular mechanisms underlying the effects of selected compounds were assessed through terminal deoxynucleotidyl transferase-mediated dUTP nick end labeling (TUNEL) assay and immunoblot analysis.
Screening of FDA-approved libraries revealed valrubicin as a potent inhibitor of OVCAR8 cell proliferation and SKOV3 and A2780 cell growth. Furthermore, valrubicin treatment led to increased DNA fragmentation, as evidenced by the TUNEL assay, and activated apoptosis signaling through enhancement of cleaved caspase-3 and poly(ADP-ribose) polymerase levels.
Valrubicin, through drug repositioning, can be applied as a new therapeutic agent for OC.